Transcenta Announces First Patient Dosed In Phase Iia Study Of Claudin182 Monoclonal Antibody Tst001 Combined With Cisplatin And Gemcitabine For The First Line Treatment Of Biliary Tract Cancer
Transcenta Announces First Patient Dosed In Phase Iia Study Of Claudin18.2 Monoclonal Antibody Tst001 Combined With Cisplatin And Gemcitabine For The First Line Treatment Of Biliary Tract Cancer
Transcenta Holding Limited A Clinical Stage Biopharmaceutical Company With Fully-Integrated Capabilities In Discovery, Research, Development And Manufacturing Of Antibody-Based Therapeutics, Announces The Successful Dosing Of First Patient In China Phase Iia Study Of Tst001, A Claudin18.2 Monoclonal Antibody, Combined With Cisplatin And Gemcitabine For The First Line Treatment Of Systemic Treatment-Na
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!